Torrent Pharma semaglutide Brazil launch eyed within nine months as Brazil sales rise 38 percent
Torrent Pharmaceuticals says it hopes to sell semaglutide in Brazil within six to nine months after Brazil revenue rose 38% in rupees and 20% in local currency. No regulatory filing or approval has been disclosed.
What's new
Torrent Pharmaceuticals MD Aman Mehta said the company optimistically expects to launch semaglutide in Brazil within six to nine months, as Brazil revenue rose 38% to Rs 440 crore in Q2 FY27.
Why it matters
Brazil would be Torrent's first semaglutide market outside India, where it holds a 32% combined share. A local rival's generic entry has already sped up growth in Brazil's semaglutide category, according to the report.
What's next
No ANVISA filing or approval for Torrent semaglutide has been reported. Watch for a regulatory decision, a named supply source and an update on Torrent's third quarter call.
AHMEDABAD: Torrent Pharmaceuticals hopes to launch semaglutide in Brazil within six to nine months, Managing Director Aman Mehta said on a recent earnings call. The Torrent Pharma semaglutide Brazil plan comes as the company reported Brazil revenue of Rs 440 crore for the July to September quarter, up 38% from a year earlier, according to a Medical Dialogues report. Mehta framed the timeline as an optimistic expectation, not a fixed date. The report does not say whether Torrent has filed semaglutide with Brazil's regulator, and no approval has been announced.
What Torrent said about the Brazil launch
Mehta gave the timing on the call that followed Torrent's second quarter results for fiscal 2027, Medical Dialogues reported. He said the company optimistically expects to bring semaglutide to Brazil in six to nine months. Semaglutide is a GLP 1 receptor agonist used for type 2 diabetes and, in some formulations, obesity. Torrent has so far sold the drug only in India, one of the markets where key semaglutide patents have lapsed. The comments as reported gave no product form, brand name or manufacturing source for Brazil. They also did not say whether a launch would cover the injectable form, the oral form or both. Each form is a separate product for regulators and for factories, so the answer shapes the timeline.
Brazil's National Health Surveillance Agency, known as ANVISA, decides which medicines can be sold in the country. Torrent said it has 53 products under ANVISA review, but the report does not list them, so it is not clear whether semaglutide is one of them. Mehta tied the plan to recent moves in the Brazilian market. According to the report, a major local company entered the generic semaglutide segment in the past three months, and that entry has sped up growth in the category. The report did not name the company. Torrent's view is that a growing market leaves room for another seller. That is a company view, and the timing depends on a regulator the company does not control.
Brazil revenue rose faster in rupees than in reais
In rupee terms, Torrent Brazil revenue reached Rs 440 crore in the second quarter of fiscal 2027, a 38% rise from a year earlier, the report said. In local currency the gain was smaller. Revenue rose 20% to 236 million reais on a constant currency basis, which strips out exchange rate moves. The gap between the two figures means currency shifts added a large part of the headline growth in rupees. Even so, the underlying business grew faster than its market. Citing IQVIA, the report said Torrent grew 26% in the quarter while the overall Brazilian market grew 6%. Mehta credited the company's leading brands and new product launches for the gain.
Citing IQVIA, the report said Torrent grew 26% in the quarter while the overall Brazilian market grew 6%.
The first half of the fiscal year shows the same pattern. Brazil revenue for April to September rose 34% to Rs 717 crore, while constant currency revenue rose 13% to 383 million reais, according to the report. Torrent runs four business units in Brazil: cardiovascular and diabetes, central nervous system, generics and non retail. Mehta said all four are performing well. He also said he expects the Brazilian business to keep growing at a mid teens rate, helped by new launches. That is a management forecast, not a result. Any Torrent Pharma semaglutide Brazil sales would come on top of these figures, since the drug has not launched there.
| Measure | Q2 FY27 | H1 FY27 |
|---|---|---|
| Brazil revenue in rupees | Rs 440 crore | Rs 717 crore |
| Growth in rupees year on year | 38% | 34% |
| Revenue in reais at constant currency | 236 million | 383 million |
| Constant currency growth | 20% | 13% |
| Torrent growth against market per IQVIA | 26% against 6% | Not reported |
| Products under ANVISA review | 53 | 53 |
Generic semaglutide in India after a supply gap
Torrent's record in India is the clearest guide to how it may run a launch abroad. The company lost injectable semaglutide supply for nearly two months, the report said, and brought in a new manufacturing partner to restore it by September. Mehta said Torrent held a combined 32% share of oral and injectable semaglutide in the second quarter, citing the Pharmatrac dataset. In the oral segment, he said, Torrent holds more than 90% of the market among generic makers. Other Indian companies have hit supply trouble as well. Dr Reddy's paused supply in July after an impurity turned up in scale up batches of the active ingredient, as this site has reported.
Mehta said the supply gap cost Torrent some of its share in the injectable semaglutide India market, but the September relaunch and the sales recovery since then give the company confidence it can win much of it back. Torrent had put the first year size of India's generic semaglutide market at about Rs 800 crore and says it is on track to reach that level. Mehta said the market could grow fast for a couple of years and then level off in the third or fourth year. He added that it is too early to size it four to five years out. On pricing, he said per patient prices should stay broadly stable or rise slowly, because Torrent sells semaglutide as a branded business.
What is not known about the Brazil plan
Several basic facts are missing from the public record so far. The report does not say when Torrent filed, or will file, a semaglutide dossier with ANVISA, and no ANVISA decision on such a product has been reported. The company has not said who will make the drug for Brazil. That question matters after the India supply break, which Torrent fixed only by adding a new partner. Peptide drugs such as semaglutide need tight control of purity and sterile filling, and recent supply breaks at two Indian makers show how production problems can delay sales. The Torrent Pharma semaglutide Brazil timeline is a company target, and it could move.
Other parts of the call point to limits on growth elsewhere. In Germany, Mehta said supply issues and government ordered price cuts have hurt the non retail business, and he expects a slight decline before stability returns in three to four quarters. Torrent expects no change this year to its workforce of about 9,100 medical representatives, though it may review an expansion to 9,500 to 9,600 next year. The figures in this story come from a Medical Dialogues account of the earnings call, which credits The Hindu BusinessLine. Torrent's own results filing and call transcript were not reviewed for this story, so the numbers stand as reported.
Conclusion
Torrent says its semaglutide could reach Brazil within six to nine months, after a quarter in which Brazil revenue rose 38% in rupees and 20% in local currency. The Torrent Pharma semaglutide Brazil launch still needs a regulatory path the company has not described in public and a supply chain that broke once in India. The next markers are an ANVISA filing or decision and Torrent's third quarter call. Our industry desk will track both.
